Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2024-08-02 00:00:00 ET · period of report 2024-07-31 · accession 0001415889-24-020687 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-08-02 | 2024-07-31 | ELVN | Kintz Samuel | Pres AND CEO, Dir | S - Sale | $27.56 | -2,270 | 1.06M | -0.2% | -$62.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-31 | S | D | 2,270 | $27.56 | 1,061,255 | I See footnote | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $27.50 to $27.655. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. |